Author's response to reviews

Title: Cardiovascular Health in Anxiety or Mood Problems Study (CHAMPS): study protocol for a randomized controlled trial

Authors:

Phillip Tully (phillip.tully@adelaide.edu.au)
Deborah A Turnbull (deborah.turnbull@adelaide.edu.au)
John D Horowitz (john.horowitz@adelaide.edu.au)
John F Beltrame (john.beltrame@adelaide.edu.au)
Terina Selkow (Terina.Selkow@health.sa.gov.au)
Elizabeth Markwick (Elizabeth.Markwick@health.sa.gov.au)
Bernhard T Baune (bernhard.baune@adelaide.edu.au)
Shannon Shannon Sauer-Zavala (shannonezavala@gmail.com)
Harald Baumeister (harald.baumeister@psychologie.uni-freiburg.de)
Gary A Wittert (gary.wittert@adelaide.edu.au)

Version: 5
Date: 13 October 2015

Author's response to reviews: see over
13th October 2015

Prof. Doug Altman University of Oxford, UK
Prof. Curt Furberg Wake Forest University of Medicine, USA
Prof. Jeremy Grimshaw Ottawa Health Research Institute, Canada
Koji Tsuboi

Dear Editors-in-Chief,

Please accept the revised manuscript “Cardiovascular Health in Anxiety or Mood Problems Study (CHAMPS): study protocol for a randomized controlled trial” as a submission to BMC Trials. Below we outline our response to the reviewer comments.

Once again I thank you for your consideration of this manuscript. With best wishes, sincerely yours.

Phillip J. Tully, PhD.
Dept. Rehabilitation Psychology
Freiburg University, Germany
Response to peer review of CHAMPS Revision 4

Can the authors consider the limitations of running an underpowered trial in the discussion section? This should consider where this trial fits along the spectrum from feasibility to pilot to definitive evaluation. It is not clear to me still how they are labelling this trial and why they are trying to detect differences in a primary outcome rather than piloting the intervention and then going for a definitive trial.

Response The study is labelled throughout the revised manuscript as a feasibility RCT. We have made changes throughout the manuscript that the feasibility RCT will inform a larger more definitive trial.